Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Morphosys Ag ADR (NQ: MOR )

18.60 +0.40 (+2.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 58,144
Open 18.20
Bid (Size) 18.10 (35)
Ask (Size) 18.75 (5)
Prev. Close 18.20
Today's Range 18.20 - 18.60
52wk Range 4.185 - 19.50
Shares Outstanding 32,890,046
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, MOR, BEST, MGOL on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire

Performance

YTD
+92.95%
+92.95%
1 Month
+2.54%
+2.54%
3 Month
+2.88%
+2.88%
6 Month
+97.66%
+97.66%
1 Year
+158.69%
+158.69%

More News

Read More
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
From MorphoSys AG
Via Business Wire
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
Via ACCESSWIRE
MorphoSys: Q4 Earnings Insights
Via Benzinga
Earnings Outlook For MorphoSys
Via Benzinga
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
MOR Stock Earnings: MorphoSys Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
MorphoSys AG Reports First Quarter 2024 Financial Results
From MorphoSys AG
Via Business Wire
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
Via Benzinga
Exposures Product Safety
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
Via ACCESSWIRE
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Via Benzinga
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
From MorphoSys AG
Via Business Wire
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
Via ACCESSWIRE
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
Via ACCESSWIRE
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From MorphoSys AG
Via Business Wire
Earnings Scheduled For March 13, 2024
Via Benzinga
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Via Talk Markets
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Via InvestorPlace
Exit Now! 3 Biotech Stocks to Sell in February 2024
Via InvestorPlace
Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B
Via Benzinga
Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion
Via Investor's Business Daily
Why Is MorphoSys (MOR) Stock Up 50% Today?
Via InvestorPlace
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.